Morgan Stanley Upgrades DexCom (DXCM), Cites Undervalued Recovery and G7 Margin Potential

DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy in 2026. On December 2, Morgan Stanley upgraded DexCom to ...

Patients with rarer types of diabetes can get up to 80% in subsidies for monitoring devices

Rarer diabetes patients in Singapore can now receive up to 80% government subsidies for continuous glucose monitoring (CGM) ...

Senseonics: Eversense 365 Is A Game Changer For The CGM Industry

Senseonics earns a buy with Eversense 365 driving growth, Q3 revenue up 90% YoY, gross margin expansion, and Ascensia ...

Medtronic’s diabetes spinoff MiniMed files for IPO

MiniMed is pitching the breadth of its portfolio as an advantage over more focused rivals such as Dexcom and Insulet.
Fierce Biotech

Editor's corner: Fierce Medtech's top 10 stories of 2025 show how tech can treat

One of the main threads running through our most-read stories of 2025—as much as ever in the medtech industry writ large—is ...
The American Journal of Managed Care

HEDIS Glycemic Goal Achieved Using Control-IQ Technology

Our study assessed the impact of using Control-IQ technology, an automated insulin delivery system, on achievement of a Healthcare Effectiveness Data and Information Set (HEDIS) quality measure ...
Endocrinology Advisor

Real-Time CGM Reduces LGA Births in Gestational Diabetes

Real-time continuous glucose monitoring (rt-CGM) reduced large-for-gestational-age (LGA) births in women with gestational diabetes.
Healio

Obesity raises mortality odds in veterans with type 1 diabetes, but CGM may be beneficial

Mortality rates are high in patients with type 1 diabetes, and overweight and obesity appear to be major factors, a speaker ...

MiniMed Group Files For IPO In Medtronic Carve-Out

Explore MiniMed Group, Inc.'s upcoming IPO, market position in diabetes devices, and key financial risks. Click for this MMED ...